Majedie Asset Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Majedie Asset Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-150,579	Closed	-$757K	–	75
2014 Q3	$757K	Hold	150,579	–	–	0.13%	32
2014 Q2	$1.01M	Hold	150,579	–	–	0.23%	12
2014 Q1	$1.09M	Hold	150,579	–	–	0.28%	11
2013 Q4	$567K	Buy	+150,579	New	+$583K	0.17%	12

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Majedie Asset Management's NWBO Position: Q4 2014 in Review

Majedie Asset Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2014, closing a stake of 150,579 shares — an estimated $757K sold.

Majedie Asset Management first reported a position in NWBO in Q4 2013 and held it in 4 quarters. The position peaked at $1.09M in Q1 2014. 70 funds tracked by Wall St. Rank hold NWBO as of Q4 2014.

Majedie Asset Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2014 after selling out during the quarter.
Majedie Asset Management sold 150,579 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2014, an estimated $757K.
Majedie Asset Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 4 quarters.
Majedie Asset Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $1.09M in Q1 2014.
70 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2014.

Based on Majedie Asset Management's 13F filing for Q4 2014, filed 4 Feb 2015.